Nov Inc
Energy
Nov Inc (NOV) Stock News
The latest NOV headlines and market coverage — 5 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
NOV Reports Second Quarter 2026 Earnings
NOV Inc. reported Q2 2026 revenues of $2.13 billion (up 4% sequentially, down 2% year-over-year) with net income of $112 million ($0.31 per share). Adjusted EBITDA increased to $283 million, benefiting from $40 million in tariff refunds. The company returned $127 million to shareholders and expects Q3 2026 revenues to be flat to up 2% with Adjusted EBITDA between $240-270 million. Management highlighted improving industry fundamentals, growing capital equipment opportunities, and successful deployment of digital and robotics solutions across offshore and onshore operations.
- GlobeNewswire Inc.·
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals announced that its Phase 3 NOVA-2 trial of LB-102 for schizophrenia will report topline results in the first half of 2027, ahead of previous guidance. The accelerated timeline reflects faster-than-expected enrollment across 25 U.S. sites. The company maintains sufficient cash runway through Q2 2029 to fund multiple clinical readouts, including Phase 2 trials in bipolar depression and adjunctive MDD.
- GlobeNewswire Inc.·
Save the Date: NOVAGOLD 2026 Second Quarter Report, Conference Call and Video Webcast
NOVAGOLD Resources will release its second quarter 2026 financial results on June 24, 2026, followed by a conference call at 8:00 am PT. The company's leadership will discuss Q2 results, Donlin Gold Bankable Feasibility Study progress, and ESG initiatives. All seven shareholder proposals were approved at the virtual annual general meeting, with 74.45% share representation.
- The Motley Fool·Neutral
ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now?
Front Street Capital Management purchased 384,124 additional shares of Enovis (ENOV) in Q1 2026 for approximately $9.08 million, increasing their stake to 2.25% of fund assets. The purchase signals institutional confidence in the medical device company despite ENOV shares being down 23.99% over the past year. Insider buying activity also suggests bullish sentiment, though the company reported a net loss of $1.14 billion in trailing twelve months.
- Benzinga·
NOV Declares Regular Quarterly Dividend and Supplemental Dividend
NOV Inc. announced a regular quarterly cash dividend of $0.09 per share payable on June 26, 2026, and a supplemental cash dividend of $0.09 per share payable on June 12, 2026, as part of its 2025 return of capital plan.